anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Insomnia is the most common sleep disorder that affects older adults. This proposed study aims to investigate the effects of two acupuncture methodology applied to three selected acupoints on the sleep quality of older adults with insomnia. The study will be a single-blind randomized controlled trial with a pre-post design and involve three parallel groups of older adult participants (aged \> 55 years) diagnosed with insomnia. The participants will be randomly allocated to three independent groups, i.e., a placebo group or one of two treatment groups, viz., a transcutaneous electrical nerve-stimulation group (Acu-TENS) or an acupressure group. The Acu-TENS group will receive a 4-week treatment comprising thrice-weekly 30-min sessions of Acu-TENS + a sleep hygiene program (SHP). The acupressure group will receive acupressure + SHP. The selected acupoints will be bilateral Sanyinjiao (SP6) on the legs and Shenmen (HT7) and Neiguan (PC6) on the wrists. The placebo group will receive a placebo stimulation+ SHP. The primary outcomes of the study will be sleep quality, insomnia index as well as actigraphy. The secondary outcomes will be heart rate variability, level of fatigue, mood, and quality of life. All the outcomes will be measured at the baseline assessment (before the treatment), post-treatment assessment (after the four weeks treatment) and follow-up assessment (two weeks after the treatment ended). It is hypothesized that the Acu-TENS + SHP treatment will better alleviate insomnia in participants than acupressure + SHP or placebo stimulation + SHP.
PROBLEM TO BE SOLVED: To provide the subject new compound obtained from the cultured product of a bacterial strain belonging to the genus Vibrio or Alteromonas and useful as a fat-soluble ultraviolet-absorbing agent. SOLUTION: This compound is expressed by the formula I, II or III. For example, the compound of the formula I has the following properties. Color, colorless; nature, oily state; molecular weight, 296; molecular formula, C13 H16 N2 O2 S2 ; solubility, soluble in methanol, acetone, etc., and scarcely soluble in water; color reactions, positive to ferrous oxide color-developing reaction, etc. The compound can be produced by culturing a microorganism belonging to the genus Vibrio or Alteromonas and capable of producing the compound and collecting the compound formed and accumulated in the cultured product. The compound of the formula I or II is preferably produced by using Vibrio sp.B-93 strain (FERM P-15734), etc., and the compound of the formula III is preferably produced by using Alteromonas sp.D-12 strain (FERM P-15733), etc.  The culture is preferably carried out by liquid culture at 30-35 deg.C and a medium pH of 7-8.
PURPOSE:To obtain a stick cosmetic having excellent shape-retainability, high releasability from a container and excellent storage stability and feeling to the skin, by compounding an ethylene-propylene copolymer having a specific melting point as a solidifying agent. CONSTITUTION:The objective stick cosmetic contains preferably 3-50wt.%, especially 3-20wt.% of an ethylene-propylene copolymer having a melting point of 80-105 deg.C (and a mol. wt. of about 300-800) as a solid lubricant. The stick cosmetic is e.g. lipstick, lip gloss, foundation, cheek rouge, eye shadow, eye liner or eyebrow pencil.
BACKGROUND: This report presents a clinical case of syndromic rod-cone dystrophy due to a splice site variant in the ARL2BP gene causing situs inversus, asthenozoospermia, unilateral renal agenesis and microcysts. The presence of renal agenesis and cryptorchidism expands the clinical manifestations due to ARL2BP variants. The detailed, long-term follow-up contributes valuable insights into disease progression, aiding clinical diagnosis and patient management.
CASE PRESENTATION: The male patient complained of photophobia as the first symptom when he was 20 years old followed by nyctalopia, loss of central visual acuity and peripheral visual field ten years later. Genetic analysis identified a likely pathogenic homozygous variant (c.294-1G > C) involving the splicing acceptor site of intron 4. Reported symptoms together with full-field stimulus threshold testing, electroretinogram and advanced multimodal imaging allowed us to recognize the typical characteristics of a mixed retinal dystrophy. Despite the end-stage retinal disease, this patient still retained a useful residual vision at 63 years and had a slow disease progression during the last 5 years of evaluation.
DISCUSSION AND CONCLUSIONS: Our findings underscore the variable clinical presentation of ARL2BP variants, emphasizing the importance of a nuanced approach in diagnosing and managing patients. The presence of renal cysts warrants consideration of a differential diagnosis, particularly with Senior-Loken (SLS), Bardet-Biedl (BBS) and Joubert syndromes (JS) but also with Short Rib Thoracic Dysplasia 9, highlighting the need for careful phenotypic evaluation in these cases.
The plethysmographic signal is typically strong on children. This provides a reliable heart rate monitor. However, to measure oxygen saturation, a quantitative value of the strength at two wavelength regions (green and red) is required. It is also not known if the normal ambient light is spectrally appropriate to analyze the video signals for oxygenation. With the current prototype of our system, we can monitor heart rate reliably and estimate oxygen saturation in adults, using normal artificial light or daylight, entering through a window. Heart rate and oxygen saturation will be extracted from the plethysmographic signal off the cheek, forehead or hand while the respiration rate may be retrieved from the plethysmographic signal off the chest area.
BACKGROUND: Primary cardiac angiosarcomas are very rare and present aggressively with high rates of metastasis. Given the poor prognosis, particularly once disease has spread, early diagnosis and multidisciplinary treatment is essential.
CASE PRESENTATION: We present the case of a 46-year-old male who presented with chest pain, intermittent fevers, and dyspnea. Workup with computed tomography scan and transesophageal echocardiography demonstrated a right atrial pseudoaneurysm. Given the concern for rupture, the patient was taken to the operating room, where resection of the pseudoaneurysm and repair using a bovine pericardial patch was performed. Histopathology report initially demonstrated perivascular lymphocyte infiltrate. Six weeks later, the patient represented with chest pain and new word finding difficulty. Workup revealed multiple solid lung, pericardial, brain, and bone nodules. Eventual biopsy of a cardiophrenic nodule demonstrated angiosarcoma, and rereview of the original pathology slides confirmed the diagnosis of primary cardiac angiosarcoma.
CONCLUSIONS: Primary cardiac angiosarcomas are often misdiagnosed given the rarity of these tumors, but early diagnosis and initiation of treatment is essential. The unique presentation of our case demonstrates that clinical suspicion for cardiac angiosarcoma should be maintained for spontaneous pseudoaneurysm originating from the right atrium.
In both hospice settings, a registered nurse establishes the wound protocol per principles of wound care and agency guidelines. The cover dressing will be removed and the wound cleansed according to agency protocol (usual care) or as needed. The RGN107 powder, contained in a small squirt bottle, will be squeezed/sprinkled on the wound at each dressing change after cleansing or until a crust is formed. Once formed, the powder will be applied only minimally to reinforce crust integrity. The peri-wound skin will receive care and the cover dressing will be applied. Minimal manipulation of the crusted area will ensue once it has formed. Frequency of dressing changes depends on wound characteristics such as exudate.
BACKGROUND: Despite improving understanding of trauma-induced coagulopathy (TIC), mortality and morbidity due to exsanguinating trauma remain high. Increased complications due to hemorrhage have been reported in blood group O, possibly due to reduced levels of von Willebrand factor (vWF).
METHODS: An urban level 1 adult trauma center registry was retrospectively queried. Patients receiving ≥6 units of pRBC within 4 ​h of presentation were included. Patient demographics, admission labs and outcomes were obtained. Univariate and multiple logistic regression analyses were performed.
RESULTS: 562 patients were identified. There were no significant differences in demographics, admission labs, or outcome between different ABO groups. After adjustment, Type A patients were more likely to be hypocoagulable compared to Type O patients (p ​= ​0.014). No mortality differences were seen between ABO types in multiple regression analysis.
CONCLUSIONS: No outcome or mortality differences were seen between ABO types, therefore factors other than vWF expression should be considered to explain coagulopathy in trauma patients.
The invention relates to medicine and veterinary science and can be used for treating mainly solid tumors. The inventive method for treating oncological diseases consisting in injecting a blood extracellular DNA destroying agent into a systemic blood circulation. Said blood extracellular DNA destroying agent can be embodied in the form of a DNAse enzyme, in particular a bovine pancreatic DNAse which is parenterally injected in doses ranging from of 50 000 Kunz units to 250 000 000 Kunz units a day every day during 5-360 days or in the form of a recombinant human DNAse. In addition, a blood extracellular DNA binding agent embodied in the form of anti-DNA antibodies can be injected into a systemic blood circulation. In addition a modified agent which modifies the chemical composition and/or conformation and/or polymery and/or an association with proteins and/or lipids and/or ribonucleic acids of the blood extracellular DNA. Said modifying agent can be embodied in the form of a enzyme-ribonuclease. An extracellular ribonuclease of a Serratia Mercenses bacterium can be used in the form of said agents.
The present invention is directed to a heat sterilized composition comprising: a protein source in an amount of 5 to 20% by weight of the composition, said protein source comprising hydrolyzed protein; wherein the protein source has been treated in a continuous process with at least one endopeptidase, typically for a finite length of time. Furthermore, the invention concerns a heat sterilized high protein composition having low viscosity and being devoid of bitterness, comprising hydrolyzed heat sensitive protein source having a degree of protein hydrolysis in NPN/TN of 20 to 50% and at least one heat inactivated endopeptidase. The present invention is furthermore directed to a continuous process for preparing a heat sterilized composition which comprises a protein source containing hydrolyzed protein, the process comprising the following steps: (i) Providing an aqueous solution of a protein source; (ii) Performing a continuous hydrolysis step wherein the aqueous solution of a protein source is treated with at least one endopeptidase by heating at 40 to 90° C. and for a finite length of time of 2 to 20 minutes; (iii) heat inactivation of the endopeptidase. The invention also concerns a method of controlling viscosity and preventing bitter taste of a heat sterilized high protein composition, the method comprising providing an aqueous solution of a protein source and continuously hydrolyzing the aqueous solution of a protein source with at least one endopeptidase prior to heat inactivation of the said endopeptidase. Finally, the invention concerns the use of hydrolyzed protein prepared in a continuous process as described herein by treatment with at least one endopeptidase for a finite length of time, for preparing a heat sterilized composition and/or for controlling the viscosity of a liquid composition, wherein the composition comprises 5 to 20 weight % total protein. The invention also concerns medical uses and treatments applying or using the inventive heat sterilized composition.
The present disclosure relates to a computer-implemented method and system for improvements to emotional and behavioral interfaces. In an example, a first group of color-coded regions is displayed representing emotions and behaviors for data collected from one or more participants using an input method. Correspondences are determined within the first group of color-coded regions. Individual ones of the first group of color-coded regions are provided with a first portion of pixels in a first color associated with a value in the data based in part on the correspondences. A second portion of pixels is provided with a second color associated with a neutral indication. Changes to the data over discrete or random intervals of time are determined as modifying the correspondences. A dynamical change is applied to the first portion of pixels and the second portion of pixels to update the display of the first group of color-coded regions.
### 

Teratogenic Effects: Pregnancy Category B.

Oral reproduction studies were performed at doses of 10 mg/kg in mice, 1000 mg/kg in rats and 125 mg/kg in rabbits. These doses correspond, in each species, respectively, to approximately 160, 32,000, and 8,000 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis. Inhalation reproduction studies were conducted in rats and rabbits at doses of 1.5 and 1.8 mg/kg, respectively, (approximately 50 and 120 times, respectively, the maximum recommended daily intranasal dose in adults on a mg/m2 basis). These studies demonstrated no evidence of teratogenic effects as a result of ipratropium bromide. At oral doses 90 mg/kg and above in rats (approximately 2,900 times the maximum recommended daily intranasal dose in adults on a mg/m2 basis) embryotoxicity was observed as increased resorption. This effect is not considered relevant to human use due to the large doses at which it was observed and the difference in route of administration. However, no adequate or well controlled studies have been conducted in pregnant women. Because animal reproduction studies are not always predictive of human response, Atrovent® (ipratropium bromide) Nasal Spray 0.03% should be used during pregnancy only if clearly needed.
Cabozantinib will be administered in the tablet form, at three dose levels: 40, 20 and 60 mg per day. Pembrolizumab will be administered as an intravenous infusion at a fixed dose of 200 mg once every 3 weeks.
All MS patients will undergo clinical and neurophysiological evaluation at baseline (T0). The baseline will consider the radiological data of disease activity obtained from the most recently performed MRI according to clinical practice. These evaluations will be repeated according to clinical practice in patients taking DMT or every 6 months, in a stable condition or according to the indication of the treating neurologist in case of disease reactivation. A one-year neurophysiological, clinical and radiological observation is foreseen. Healthy subjects will undergo only the neurophysiological evaluation at baseline.
The invention discloses an herbal conditioning foot bath concentrate and a preparation method thereof. The concentrate comprises herbal materials such as Folium Artemisiae Argyi, Flos Carthami and Flos Chrysanthemi Indici. The concentrate is made into a lotion by decocting. The lotion is poured into hot water and stirred well for a foot bath, giving convenience and high speed. The efficacy of the herbs can also be fully utilized. The materials are synergistically effective in enhancing blood circulation, warming qi and blood and improving mental condition through the combination of the herbs.
PURPOSE:A hair cosmetic, obtained by blending a quaternary ammonium salt with a phosphoric acid ester at a specific molar ratio and capable of imparting high glossing effect to the hair. CONSTITUTION:A hair cosmetic containing (A) one or two or more of quaternary ammonium salts expressed by formula I (R1 is 8-20C straight or branched chain alkyl, alkenyl, etc.; R2-R4 are methyl, ethyl, benzyl, etc.; X<-> is anion) and (B) one or two or more of phosphoric acid esters expressed by formula II (R5 is 10-22C straight-chain alkyl, hydroxyalkyl, etc.; Y is formula III or Z; R6 is H or methyl; Z is H, alkali metal, etc.; l is 0-8) to give 0.5-1.5 molar ratio of the ingredients (B) to (A). The amount of the ingredient (A) to be blended is preferably 0.05-10wt%. The above-mentioned hair cosmetic has high glossing effect even in various states and therefore is utilizable for various applications, e.g. hair rinse agent, spray or dispenser type hair conditioner, glossing spray, etc.
FIELD: organic chemistry of natural compounds. SUBSTANCE: invention describes novel taxanes of the general formula (I)   showing pharmacological activity where S K  can mean the group -OC(O)CHOHCH- ; R 1  can mean hydrogen atom or C 1 -C 10 -acyl; R 2  can mean α-OH; R 3  can mean C 1 -C 10 -alkoxy-group and free hydroxy-groups in structure (I) can be further modified functionally by esterification. Invention describes also method of their synthesis and drug based on thereof. Except for enhanced stability of microtubules, compounds of the formula (I) show additional effect on the process of tubulin polymerization and can be used for treatment of patients with malignant tumors. EFFECT: improved method of synthesis, valuable antitumor properties. 8 cl, 1 tbl, 6 ex
A GGGGCC (G4C2) hexanucleotide repeat expansion in C9ORF72 causes amyotrophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD), while a CGG trinucleotide repeat expansion in FMR1 leads to the neurodegenerative disorder Fragile X-associated tremor/ataxia syndrome (FXTAS). These GC-rich repeats form RNA secondary structures that support repeat-associated non-AUG (RAN) translation of toxic proteins that contribute to disease pathogenesis. Here we assessed whether these same repeats might trigger stalling and interfere with translational elongation. We find that depletion of ribosome-associated quality control (RQC) factors NEMF, LTN1 and ANKZF1 markedly boost RAN translation product accumulation from both G4C2 and CGG repeats while overexpression of these factors reduces RAN production in both reporter assays and C9ALS/FTD patient iPSC-derived neurons. We also detected partially made products from both G4C2 and CGG repeats whose abundance increased with RQC factor depletion. Repeat RNA sequence, rather than amino acid content, is central to the impact of RQC factor depletion on RAN translation-suggesting a role for RNA secondary structure in these processes. Together, these findings suggest that ribosomal stalling and RQC pathway activation during RAN translation inhibits the generation of toxic RAN products. We propose augmenting RQC activity as a therapeutic strategy in GC-rich repeat expansion disorders.
Total hip replacement (THR) has been a sucessful treatment for cases of degenerative joint diseases. However, post operative complications such as dislocations, osteolysis, component wear and migration are still a concern. It has been noted in the scientific literature that precise acetabular cup position helps reduce such post operative complications. The Pelvic Alignment Level (PAL) offers this solution by assessing pelvic motion and optimizing implant position without the need for intra-operative fluoroscopy or a large capital expenditure. The focus of this study is to evaluate the clinical outcomes (acetabular cup placement, femoral offset, and leg length) of using the PAL instrument to those without using PAL instrument during total hip replacement. This will be a prospective, post market, randomized multi-center clinical study.
Patients in this group wil receive 2 mL of water PO 2 minutes prior to vaccination, then they will rest in crib during cleansing of the right tigh, during injection of the right tigh for hepatitis B vaccination and 2 minutes after the injection. Infants will not receive any handling during the whole procedure outside the prespecified above.
UDENYCA is administered subcutaneously via a single-dose prefilled autoinjector, a single-dose prefilled syringe for manual use or for use with the on-body injector (OBI) for UDENYCA, which is co-packaged with a single dose prefilled syringe for OBI. Use of the OBI for UDENYCA is not recommended for patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome. Use of the OBI has not been studied in pediatric patients. 

Prior to use‚ remove the carton from the refrigerator and allow UDENYCA to reach room temperature for a minimum of 30 minutes. Discard any UDENYCA left at room temperature for greater than 48 hours.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer UDENYCA if discoloration or particulates are observed. 

The needle cap on the prefilled syringe and prefilled autoinjector is not made with natural rubber latex.

Pediatric Patients Weighing Less than 45 kg

The UDENYCA prefilled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg). The syringe does not bear graduation marks which are necessary to accurately measure doses of UDENYCA less than 0.6 mL (6 mg) for direct administration to patients. Thus, the direct administration to patients requiring dosing of less than 0.6 mL (6 mg) is not recommended due to the potential for dosing errors. Refer to Table 1.

The UDENYCA prefilled autoinjector is not suitable for use in pediatric patients weighing less than 45 kg. The UDENYCA prefilled autoinjector delivers the entire contents (6 mg in 0.6 mL) in a single injection and is not adjustable.
PURPOSE: A pharmaceutical composition for anti-cancer containing protein extract isolated from Solanum tuberosum L., cv. Gogu valley or peptide isolated from the protein extract is provided to ensure function of suppressing skin cancer and gastric cancer. CONSTITUTION: A pharmaceutical composition for anticancer contains protein extract isolated from Solanum tuberosum L., cv. Gogu valley. The cancer is skin cancer or gastric cancer. The protein extract is used in the form of liquid, tablet, granule, capsule, suspension, syrup, ointment or injection.
Patients receive nivolumab IV over 30 minutes on days 1, 15, and 29 and ipilimumab IV over 30 minutes on day 1. Treatment repeats every for 6 weeks for 2 cycles in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of cycle 2, patients also undergo IMRT 5 days a week (Monday-Friday) for 6 weeks in the absence of disease progression or unacceptable toxicity.
Title protein with a carbohydrate part of pref. 13%, an isoelectric point in weakly acidic range at pref. pH 4.8-5.2; electrophoretic behaviour of serum alpha1-protein, a sedimentation constant in ultra-centrifuge of 9.5 plus-or-minus 0.5 S; a mol. wt. of 300,000 plus-or-minus 30,000, has the ability to bind cations, esp. metal ions such as Ca, Ba and Ni with which it can crystallise. It also can precipitate with a specific anti-serum. It can be isolated from aq. human blood at pH 6 by treatment with carboxymethylcellulose, eluting with a NH4HCO3-water gradient. The eluate is purified by zone electrophoresis on polyvinylchloride granules as carrier at pH 8.6 and the isolated zone is further purified by gel filtration with exclusion limit of 150,000. The protein is an antigen which can induce specific antibodies upon injection into rabbits. The process used is simpler than known processes and gives ca. 60% yield.